It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The health, economic, and social burden of neglected tropical diseases (NTDs) in Africa remains substantial, with elimination efforts hindered by persistent sociopolitical instability, including ongoing conflicts among political and ethnic groups that lead to internal displacement and migration. Here, we explore how innovative technologies can support Africa in addressing NTDs amidst such instability, through analysis of WHO and UNHCR data and a systematic literature review. Countries in Africa facing sociopolitical instability also bear a high burden of NTDs, with the continent ranking second globally in NTD burden (33%, 578 million people) and first in internal displacement (50%, 31.6 million people) in 2023. Studies have investigated technologies for their potential in NTD prevention, surveillance, diagnosis, treatment and management. Integrating the evidence, we discuss nine promising technologies—artificial intelligence, drones, mobile clinics, nanotechnology, telemedicine, augmented reality, advanced point-of-care diagnostics, mobile health Apps, and wearable sensors—that could enhance Africa’s response to NTDs in the face of persistent sociopolitical instability. As stability returns, these technologies will evolve to support more comprehensive and sustainable health development. The global health community should facilitate deployment of health technologies to those in greatest need to help achieve the NTD 2030 Roadmap and other global health targets.
Countries in Africa facing sociopolitical instability also bear a high burden of neglected tropical diseases (NTDs). Here, the authors explore the potential of health technologies to address NTDs through a systematic literature review.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688)
2 Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X); Addis Ababa University, School of Public Health, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688)
3 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); King’s College London, Centre for Global Mental Health, Health Services and Population Research Department, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); Addis Ababa University, Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688)
4 Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X)
5 University of Sussex, Science Policy Research Unit, Brighton, UK (GRID:grid.12082.39) (ISNI:0000 0004 1936 7590)
6 University of Khartoum, Institute of Endemic Diseases, Khartoum, Sudan (GRID:grid.9763.b) (ISNI:0000 0001 0674 6207)
7 University of Rwanda, Center for Human Genetics, College of Medicine and Health Sciences, Kigali, Rwanda (GRID:grid.10818.30) (ISNI:0000 0004 0620 2260)
8 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Haramaya University, College of Health and Medical Sciences, Harar, Ethiopia (GRID:grid.192267.9) (ISNI:0000 0001 0108 7468)
9 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Queen Mary University of London, Health Economics and Policy Research Unit, Wolfson Institute of Population Health, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
10 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X); Addis Ababa University, Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688)